 Hoth Therapeutics Inc NASDAQ: HOTH plans to expand the development of the HT-003 active pharmaceutical ingredient API to pursue a new indication for the treatment of inflammatory bowel diseases IBDs, including Crohns disease and ulcerative colitis. The company has executed an option agreement with Isoprene Pharmaceuticals to investigate the potential. 